The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma
Open accessAbstract
Glioblastoma is one of the most fatal cancers, characterized by a strong vascularized phenotype. YKL-40, a secreted glycoprotein, is overexpressed in patients with glioblastomas and has potential as a novel tumor biomarker. The molecular mechanisms of YKL-40 in glioblastoma development, however, are poorly understood. Here, we aimed to elucidate the role YKL-40 plays in the regulation of VEGF expression, tumor angiogenesis, and radioresistance. YKL-40 up-regulated VEGF expression in glioblastoma cell line U87, and both YKL-40 and VEGF synergistically promote endothelial cell angiogenesis. Interestingly, long term inhibition of VEGF up-regulated YKL-40. YKL-40 induced coordination of membrane receptor syndecan-1 and integrin αvβ5, and triggered a signaling cascade through FAK(397) to ERK-1 and ERK-2, leading to elevated VEGF and enhanced angiogenesis. In addition, γ-irradiation of U87 cells increased YKL-40 expression that protects cell death through AKT activation and also enhances endothelial cell angiogenesis. Blockade of YKL-40 activity or expression decreased tumor growth, angiogenesis, and metastasis in xenografted animals. Immunohistochemical analysis of human glioblastomas revealed a correlation between YKL-40, VEGF, and patient survival. These findings have shed light on the mechanisms by which YKL-40 promotes tumor angiogenesis and malignancy, and thus provide a therapeutic target for tumor treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483
Genes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., McLendon, R. E., Bigner, D. D., & Rich, J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1010 · Cited by 1,345
Prewett, M. C., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K. D., Overholser, J. C., Hooper, A. T., Pytowski, B., Witte, L., et al. (1999) · PubMed · Cited by 713
Guo, D., Jia, Q., Song, H.-Y., Warren, R. S., & Donner, D. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.12.6729 · Cited by 482
Abedi, H., & Zachary, I. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.24.15442 · Cited by 471
A public database for gene expression in human cancers.
Lal, A., Lash, A., Altschul, S. F., Velculescu, V. E., Zhang, L., McLendon, R. E., Marra, M. A., Prange, C. K., Morin, P. J., Polyák, K., et al. (1999) · PubMed · Cited by 414
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
Millauer, B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A., & Strawn, L. M. (1996) · PubMed · Cited by 413
Renkema, G. H., Boot, R. G., Au, F. L., Donker‐Koopman, W. E., Strijland, A., Muijsers, A. O., Hrebicek, M., & Aerts, J. M. F. G. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2510504.x · Cited by 402
RECKLIES, A. D., WHITE, C., & LING, H. (2002) · Biochemical Journal · doi:10.1042/bj20020075 · Cited by 388
Nigro, J. M., Misra, A., Zhang, L., Smirnov, I., Colman, H., Griffin, C., Ozburn, N., Chen, M., Pan, E., Koul, D., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2921 · Cited by 325
YKL-40, a secreted glycoprotein, promotes tumor angiogenesis
Shao, R., Hamel, K., Petersen, L., Cao, Q. J., Arenas, R. B., Bigelow, C., Bentley, B., & Yan, W. (2009) · Oncogene · doi:10.1038/onc.2009.292 · Cited by 292
Self-citationIdentification of proteins secreted by human osteoblastic cells in culture
Johansen, J. S., Williamson, M. K., Rice, J. S., & Price, P. A. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070506 · Cited by 269
Differential αv integrin–mediated Ras-ERK signaling during two pathways of angiogenesis
Hood, J. D., Frausto, R., Kiosses, W. B., Schwartz, M. A., & Cheresh, D. A. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200304105 · Cited by 262
Wheeler-Jones, C., Abu-Ghazaleh, R., Cospedal, R., Houliston, R. A., Martin, J., & Zachary, I. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01481-6 · Cited by 255
Malinda, K. M., Ponce, L., Kleinman, H. K., Shackelton, L. M., & Millis, A. J. T. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4511 · Cited by 254
Serum YKL-40 is increased in patients with hepatic fibrosis
Johansen, J. S., Christoffersen, P., Møller, S., Price, P. A., Henriksen, J. H., Garbarsch, C., & Bendtsen, F. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80095-1 · Cited by 252
Tanwar, M. K., Gilbert, M. R., & Holland, E. C. (2002) · PubMed · Cited by 241
Crystal Structure and Carbohydrate-binding Properties of the Human Cartilage Glycoprotein-39
Fusetti, F., Pijning, T., Kalk, K. H., Bos, E., & Dijkstra, B. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303137200 · Cited by 235
Létuvé, S., Kozhich, A., Arouche, N., Grandsaigne, M., Reed, J., Dombret, M.-C., Kiener, P. A., Aubier, M., Coyle, A. J., & Pretolani, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.5167 · Cited by 217
Jensen, B. V., Johansen, J. S., & Price, P. A. (2003) · PubMed · Cited by 209
Pelloski, C. E., Mahajan, A., Maor, M., Chang, E. L., Woo, S., Gilbert, M., Colman, H., Yang, H., Ledoux, A., Blair, H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1765 · Cited by 207
MMP‐2 alters VEGF expression via αVβ3 integrin‐mediated PI3K/AKT signaling in A549 lung cancer cells
Chetty, C., Lakka, S. S., Bhoopathi, P., & Rao, J. S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25134 · Cited by 205
VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2
Zhang, Z., Neiva, K. G., Lingen, M. W., Ellis, L. M., & Nör, J. E. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.152 · Cited by 197
De Ceuninck, F., Gaufillier, S., Bonnaud, A., Sabatini, M., Lesur, C., & Pastoureau, P. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5253 · Cited by 196
Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells
Li, H.-F., Kim, J.-S., & Waldman, T. (2009) · Radiation Oncology · doi:10.1186/1748-717x-4-43 · Cited by 190
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
Verhoeff, J. J., van Tellingen, O., Claes, A., Stalpers, L. J., van Linde, M. E., Richel, D. J., Leenders, W. P., & van Furth, W. R. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-444 · Cited by 189
Serum YKL-40 and colorectal cancer
Cintin, C., Johansen, J. S., Christensen, I. J., Price, P. A., Sørensen, S., & Nielsen, H. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690238 · Cited by 187
Activation of tumor cell integrin α v β 3 controls angiogenesis and metastatic growth in the brain
Lorger, M., Krueger, J. S., O'Neal, M., Staflin, K., & Felding-Habermann, B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903035106 · Cited by 185
Volck, B., Johansen, J. S., Stoltenberg, M., Garbarsch§, C., Price, P. A., Østergaard, M., Ostergaard, K., Løvgreen-Nielsen, P., Sonne-Holm, S., & Lorenzen, I. (2001) · Osteoarthritis and Cartilage · doi:10.1053/joca.2000.0377 · Cited by 182
Hormigo, A., Gu, B., Karimi, S., Riedel, E., Panageas, K. S., Edgar, M. A., Tanwar, M. K., Rao, J. S., Fleisher, M., DeAngelis, L. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0181 · Cited by 182
Faibish, M., Francescone, R., Bentley, B., Yan, W., & Shao, R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0868 · Cited by 181
Self-citationPelloski, C. E., Lin, E., Zhang, L., Yung, W. K. A., Colman, H., Liu, J.-L., Woo, S. Y., Heimberger, A. B., Suki, D., Prados, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2202 · Cited by 179
Yan, W., & Shao, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601856200 · Cited by 169
Self-citationInoue, T., & Meyer, T. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003068 · Cited by 140
High serum YKL‐40 level after surgery for colorectal carcinoma is related to short survival
Cintin, C., Johansen, J. S., Christensen, I. J., Price, P. A., Sørensen, S., & Nielsen, H. J. (2002) · Cancer · doi:10.1002/cncr.10644 · Cited by 137
Johansen, J. S., Christensen, I. J., Riisbro, R., Greenall, M. J., Chen, H., Price, P. A., Smith, K., Brünner, N., & Harris, A. L. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024431000710 · Cited by 128
Bevacizumab and Recurrent Malignant Gliomas: A European Perspective
Wick, W., Weller, M., van den Bent, M. J., & Stupp, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9027 · Cited by 126
Kirkpatrick, R. B., Emery, J., CONNOR, J., Dodds, R. A., Lysko, P. G., & ROSENBERG, M. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3764 · Cited by 117
Saidi, A., Javerzat, S., Bellahcène, A., Vos, J. D., Bello, L., Castronovo, V., Deprez, M., Loiseau, H., Bikfalvi, A., & Hagedorn, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.23313 · Cited by 113
High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival
Høgdall, E. V. S., Johansen, J. S., Kjær, S. K., Price, P., Christensen, L. H., Blaakær, J., Bock, J. E., Glud, E., & Høgdall, C. K. (2003) · Oncology Reports · doi:10.3892/or.10.5.1535 · Cited by 89
Bergmann, O. J., Johansen, J. S., Klausen, T. W., Mylin, A. K., Kristensen, J. S., Kjeldsen, E., & Johnsen, H. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1317 · Cited by 78
Dreyfuss, J. M., Johnson, M. D., & Park, P. J. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-71 · Cited by 65
Sharif, M., Granell, R., Johansen, J. S., Clarke, S., Elson, C. J., & Kirwan, J. (2005) · Lara D. Veeken · doi:10.1093/rheumatology/kei216 · Cited by 46
Ido, K., Nakagawa, T., Sakuma, T., Takeuchi, H., Sato, K., & Kubota, T. (2008) · Neuropathology · doi:10.1111/j.1440-1789.2008.00926.x · Cited by 38
Angiogenic factors in plasma of brain tumour patients.
İlhan, A., Gärtner, W., Neziri, D., Czech, T., Base, W., Hörl, W. H., & Wagner, L. (2009) · PubMed · Cited by 25
Cited by
Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., & Xiao, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01744-8 · Cited by 977
Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis
Riabov, V., Gudima, A., Wang, N., Mickley, A., Orekhov, A., & Kzhyshkowska, J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00075 · Cited by 628
Chitinase-3 like-protein-1 function and its role in diseases
Zhao, T., Su, Z., Li, Y., Zhang, X., & You, Q. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00303-7 · Cited by 536
YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
Llorens, F., Thüne, K., Tahir, W., Kanata, E., Diaz-Lucena, D., Xanthopoulos, K., Kovatsi, E., Pleschka, C., Garcia-Esparcia, P., Schmitz, M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0226-4 · Cited by 249
Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer
Yu, J. E., Yeo, I. J., Han, S.-B., Yun, J., Kim, B., Yong, Y. J., Lim, Y.-S., Kim, T. H., Son, D. J., & Hong, J. T. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01131-9 · Cited by 109
Metadata
- Authors
- Francescone, R. A., Scully, S., Faibish, M., Taylor, S. L., Oh, D., Moral, L., Yan, W., Bentley, B., & Shao, R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 286
- Issue
- 17
- Pages
- 15332-15343
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2052883386
- Cited by
- 261
- References
- 53
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.